Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

Universitat Autònoma de Barcelona, Barcelona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:5City/State/Province:Barcelona
Treatments:ChemotherapyHospital:Universitat Autònoma de Barcelona
Drugs:Journal:Link
Date:Apr 2015

Description:

Patients:
This phase 3 study involved previously treated metastatic colorectal carcinoma patients who were divided into two separate treatment groups. Group A had 536 patients with an average age of 62 years and 54% male. Group B had 536 patients with an average age of 62 years and 61% male.

Treatment:
Patients in group A received biologic therapy with ramucirumab (a monoclonal antibody for VEGFR-2 that inhibits tumor growth) and chemotherapy with irinotecan, leucovorin, and fluorouracil (FOLFIRI).

Patients in group B received chemotherapy with irinotecan, leucovorin, and fluorouracil (FOLFIRI).

Toxicities:
There were eight treatment-related deaths in group A due to intestinal perforations and hemorrhaging, heart failure, and septic shock. Grade 4 neutropenia and diarrhea were also reported.

There were five treatment-related deaths in group B due to intestinal hemorrhaging, heart failure, liver failure, and bronchopulmonary aspergillosis (lung inflammation). Grade 4 neutropenia and diarrhea were also reported.

Results:
The median overall survival for groups A and B was 13.3 and 11.7 months, respectively.

Support:
This study was supported by Eli Lilly.

Correspondence: Dr. Josep Tabernero; email: [email protected]



Back